Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
The quick ratio measures a company's ability to meet its short-term obligations with its most liquid assets. It is calculated as a company's Total Current Assets excludes Total Inventories divides by its Total Current Liabilities. Concord Biotech's quick ratio for the quarter that ended in Jun. 2026 was 0.00.
Concord Biotech has a quick ratio of 0.00. It indicates that the company cannot currently fully pay back its current liabilities.
The historical rank and industry rank for Concord Biotech's Quick Ratio or its related term are showing as below:
NSE:CONCORDBIO'
s Quick Ratio Range Over the Past 10 Years
Min: 2.69 Med: 4.56 Max: 5.46
Current: 5.46
During the past 7 years, Concord Biotech's highest Quick Ratio was 5.46. The lowest was 2.69. And the median was 4.56.
NSE:CONCORDBIO's Quick Ratio is ranked better than 62.51% of 1411
companies
in the Biotechnology industry
Industry Median: 3.59
vs NSE:CONCORDBIO: 5.46
Concord Biotech (NSE:CONCORDBIO) Quick Ratio Explanation
The quick ratio is more conservative than the Current Ratio because it excludes inventories from current assets. The ratio derives its name presumably from the fact that assets such as cash and marketable securities are quick sources of cash. Inventories generally take time to be converted into cash, and if they have to be sold quickly, the company may have to accept a lower price than book value of these inventories. As a result, they are justifiably excluded from assets that are ready sources of immediate cash.
In general, low or decreasing quick ratios generally suggest that a company is over-leveraged, struggling to maintain or grow sales, paying bills too quickly or collecting receivables too slowly. On the other hand, a high or increasing quick ratio generally indicates that a company is experiencing solid top-line growth, quickly converting receivables into cash, and easily able to cover its financial obligations. Such companies often have faster inventory turnover and cash conversion cycles.
The higher the quick ratio, the better the company's liquidity position.
Concord Biotech Quick Ratio Related Terms
Concord Biotech Quick Ratio Historical Data
* Premium members only.
The historical data trend for Concord Biotech's Quick Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
NSE:CONCORDBIO vs VRTX, REGN, RVMD: Quick Ratio Comparison
For the Biotechnology subindustry, Concord Biotech's Quick Ratio, along with its competitors' market caps and Quick Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Concord Biotech Quick Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Concord Biotech's Quick Ratio distribution charts can be found below:
* The bar in red indicates where Concord Biotech's Quick Ratio falls into.
The quick ratio measures a company's ability to meet its short-term obligations with its most liquid assets. For this reason, the ratio excludes inventories from current assets.
Concord Biotech's Quick Ratio for the fiscal year that ended in Mar. 2026 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Concord Biotech (NSE:CONCORDBIO) has a Quick Ratio of 0.00 as of Jun. 2026. Quick ratio is the ratio of current assets less inventory to current liabilities. View historical data on Concord Biotech and its competitors. Over the past decade, Concord Biotech's Quick Ratio has ranged from 2.69 to 5.46. According to the industry distribution chart, Concord Biotech ranks #529 out of 1411 companies in the Biotechnology industry, placing it in the top 37.5%.
Is Concord Biotech's Quick Ratio too high?
Concord Biotech's current Quick Ratio is 0.00. Over the past 10 years, this metric has ranged from a low of 2.69 to a high of 5.46. Based on the distribution chart, Concord Biotech ranks #529 out of 1411 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Concord Biotech has a GF Score™ of 89/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Concord Biotech's Quick Ratio compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Concord Biotech ranks #529 out of 1411 companies for Quick Ratio. This puts Concord Biotech in the upper half of its industry. The industry median Quick Ratio is 3.59. Historically, Concord Biotech's own Quick Ratio has ranged from 2.69 to 5.46 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Quick Ratio for a Biotechnology company?
The median Quick Ratio among Biotechnology companies is 3.59, based on 1,411 companies in the industry. Companies in the top quartile (top 25%) have a Quick Ratio significantly above this median, while those in the bottom quartile fall well below. However, Quick Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Quick Ratio mean?
A high Quick Ratio can signal that a stock is expensive relative to its fundamentals. Quick ratio is the ratio of current assets less inventory to current liabilities. View historical data on Concord Biotech and its competitors. For the Biotechnology industry, the median Quick Ratio is 3.59 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Concord Biotech's current Quick Ratio is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Concord Biotech stock overvalued right now?
Based on GuruFocus' analysis, Concord Biotech (NSE:CONCORDBIO) is currently considered Fairly Valued. The stock's GF Value™ is ₹1,681.38, compared to a current price of ₹1,571.30 — trading 6.5% below its estimated fair value. The current Quick Ratio is 0.00. Concord Biotech's overall GF Score™ is 89/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Quick Ratio calculated?
Quick Ratio is calculated from a company's financial statements. For Concord Biotech (NSE:CONCORDBIO), the current Quick Ratio is 0.00 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Concord Biotech (NSE:CONCORDBIO) Overvalued in 2026?
Based on GuruFocus' analysis, Concord Biotech stock appears to be undervalued.
The current stock price of ₹1,571.30 is trading 6.5% below its estimated GF Value™ of ₹1,681.38.
GuruFocus considers Concord Biotech to be Fairly Valued.
Key valuation signals for NSE:CONCORDBIO:
Quick Ratio: 0.00
GF Value™: ₹1,681.38 vs. price of ₹1,571.30 (6.5% below fair value)
No single metric tells the full story. See the NSE:CONCORDBIO stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Concord Biotech Ltd is a research and development-driven biopharma company that manufactures Active Pharmaceutical Ingredients (API) through fermentation and semi-synthetic process and finished formulations. It is mainly engaged in the business of manufacturing and trading in pharmaceutical products. Geographically Company operates in two segments within India and outside India, having majority revenue from India.
89GF Score
Get the complete analysis for NSE:CONCORDBIO
Quick Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NSE:CONCORDBIO has been successfully added to your 
